There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Horizon Pharma Inc (NASDAQ:HZNP) and Iovance Biotherapeutics Inc (NASDAQ:IOVA) with bullish sentiments.
Horizon Pharma Inc (HZNP)
Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Horizon Pharma Inc today and set a price target of $25. The company’s shares closed yesterday at $18.42.
Rivkind Koffler noted:
“We believe enrollment and timeline targets are ambitious but continue to monitor the company’s progress. HZNP shares have already been weak into this event in spite of a positive teprotumumab conference presentation for thyroid eye disease (contact us for a transcript of our endocrinologist call). We reiterate our Buy rating and $25 PT.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 9.6% and a 44.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Horizon Pharma Inc with a $23.44 average price target, implying a 27.3% upside from current levels. In a report issued on October 4, Cantor Fitzgerald also maintained a Buy rating on the stock with a $21 price target.
.
See today’s analyst top recommended stocks >>
Iovance Biotherapeutics Inc (IOVA)
Cowen & Co. analyst Boris Peaker reiterated a Buy rating on Iovance Biotherapeutics Inc today. The company’s shares closed yesterday at $10.69.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.4% and a 40.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Iovance Biotherapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $26.25, representing a 145.6% upside. In a report issued on October 2, Chardan Capital also reiterated a Buy rating on the stock with a $30 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
